Management of AIDS-Defining Cancers
Summary
- First-line treatment options for patients with DLBCL include CHOP (doxorubicin, cyclophosphamide, vincristine, prednisolone) or infusional therapies such as EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) (Management Guidelines)[BHIVA HIV Cancer; Barta 2013; Mounier 2006; Messori 2001] combined with ART
- Rituximab has demonstrated efficacy against AIDS-related lymphomas in combination with CHOP,[Ribera 2012] EPOCH,[Sparano 2010] and dose-adjusted EPOCH[Dunleavy 2010; Dunleavy 2012] and should be administered concomitantly but with caution in those with profound immunodeficiency (CD4+ cell count < 50 cells/mm3)[BHIVA HIV Cancer]
- A meta-analysis showed that rituximab plus dose-adjusted EPOCH was associated with longer survival than rituximab plus CHOP among patients with CD20+ HIV-associated lymphoma[Barta 2013]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Cancer